CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
Clinical trial NCT02514967 · TERMINATED
Trial details
- NCT number
- NCT02514967
- Sponsor
- Anthera Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-01
- Primary completion
- 2016-11-01
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.